Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
暂无分享,去创建一个
D. Stoppa-Lyonnet | C. Callens | S. Cecere | Alexandre Eeckhoutte | A. Briaux | Manuel Rodrigues | Marc-Henri Stern | I. Vergote | N. Colombo | Guillaume Bataillon | I. Ray-Coquard | Eric Pujade-Lauraine | E. Frouin | T. Popova | I. Bieche | Victor Renault | Lucie Karayan-Tapon | Tristan Rochelle | F. Heitz | Maria Jesús Rubio Pérez | Christoph Grimm | Trine Jakobi Nøttrup | K. Yonemori
[1] P. Neven,et al. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. , 2023, European journal of cancer.
[2] D. Berton,et al. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial , 2023, JCO precision oncology.
[3] Rebecca A Dagg,et al. Targeting DNA damage response pathways in cancer , 2022, Nature Reviews Cancer.
[4] A. Vincent-Salomon,et al. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. , 2022, JAMA oncology.
[5] F. Bidard,et al. Expanding biomarkers for PARP inhibitors , 2022, Nature Cancer.
[6] Hsin-Ta Wu,et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes , 2022, Nature Cancer.
[7] C. Genestie,et al. 2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers , 2022, Ovarian cancer.
[8] C. Genestie,et al. 2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial , 2022, Ovarian cancer.
[9] M. Tiemann,et al. 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial , 2022, Pathology.
[10] I. Vergote,et al. 2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection , 2022, Ovarian cancer.
[11] I. Ray-Coquard,et al. LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) , 2022, Annals of Oncology.
[12] G. Lou,et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) , 2022, Gynecologic Oncology.
[13] B. Monk,et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Ray-Coquard,et al. 201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative , 2021, Ovarian cancer.
[15] I. Soubeyran,et al. Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. , 2020, Journal of the National Cancer Institute.
[16] François-Clément Bidard,et al. ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing , 2020, Bioinform..
[17] F. Marmé,et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.
[18] B. Monk,et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.
[19] Gabe S. Sonke,et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.
[20] E. Bongaerts,et al. Manuscript , 2018 .
[21] James X. Sun,et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[22] J. Reis-Filho,et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes , 2017, Nature Communications.
[23] E. Lander,et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.
[24] E. Birney,et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.
[25] Tatiana Popova,et al. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications. , 2016, Cancer research.
[26] A. Vincent-Salomon,et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.
[27] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[28] Yangho Chen,et al. Supplementary Methods , 2012, Acta Neuropsychiatrica.
[29] Z. Szallasi,et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.
[30] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[31] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.